Parkinson’s is a progressive neurological condition affecting over 166,000 people in the UK and 11.8 million worldwide. Our mission is to find a cure by funding research to slow, stop or reverse its progression. Progress is often delayed by the difficulty of confirming whether treatments reach the brain and work as intended. SLEIPNIR addresses this by identifying the most promising drugs earlier, allowing researchers to focus time and resources on those most likely to succeed.

We fund innovative Parkinson’s research to overcome a key barrier in drug development: uncertainty over whether treatments reach and act in the brain. Through SLEIPNIR, a multi-arm clinical trial platform, researchers will test multiple potential disease-modifying therapies to evaluate safety and target engagement. This helps to ensure only the most promising treatments, with the greatest chance of success, progress into later-stage clinical trials.